Insider Transactions in Q1 2024 at Mineralys Therapeutics, Inc. (MLYS)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 12
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,348
+10.24%
|
$6,348
$1.08 P/Share
|
|
Mar 11
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,017
+9.24%
|
$0
$0.54 P/Share
|
|
Feb 12
2024
|
Samsara Bio Capital Gp, LLC |
BUY
Open market or private purchase
|
Indirect |
555,555
+9.87%
|
$7,222,215
$13.5 P/Share
|
|
Feb 12
2024
|
Srinivas Akkaraju Director |
BUY
Grant, award, or other acquisition
|
Indirect |
555,555
+9.87%
|
$7,222,215
$13.5 P/Share
|
|
Feb 12
2024
|
Ra Capital Management, L.P. |
BUY
Grant, award, or other acquisition
|
Indirect |
1,672,508
+35.92%
|
$21,742,604
$13.5 P/Share
|
|
Feb 12
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,366
+12.11%
|
$0
$0.81 P/Share
|
|
Jan 12
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,348
+16.17%
|
$6,348
$1.08 P/Share
|
|
Jan 11
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,017
+15.89%
|
$0
$0.54 P/Share
|